ArpC3's role in insulin release in type 2 diabetes
ArpC3-mediated actin remodeling in insulin granule exocytosis and diabetes
This project looks at whether changing a protein called ArpC3 can fix actin structures in insulin-producing beta cells to help people with type 2 diabetes release insulin better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11247460 on NIH RePORTER |
What this research studies
This project looks at how the protein ArpC3 alters the meshwork of actin filaments that sit beneath the surface of insulin-producing beta cells, because that mesh helps control how insulin-packed granules get out of the cell. Researchers will use high-resolution imaging and lab functional tests on beta cells and tissue samples (including human-derived material and experimental models) to watch local actin breakdown-and-rebuild cycles near insulin granules. They will change ArpC3 activity in the lab to see whether restoring normal actin remodeling improves insulin release. The team aims to identify molecular steps that could become targets for new treatments to restore beta cell function in type 2 diabetes.
Who could benefit from this research
Good fit: Adults with type 2 diabetes who have problems with insulin secretion would be the patients most likely to benefit from this work.
Not a fit: People with type 1 diabetes or those whose diabetes is driven mainly by insulin resistance rather than beta cell failure may not directly benefit from findings focused on beta cell actin remodeling.
Why it matters
Potential benefit: If successful, the work could point to new ways to restore insulin secretion and improve blood sugar control for people with type 2 diabetes.
How similar studies have performed: Prior studies show that correcting abnormal actin remodeling can restore insulin secretion, but specifically targeting ArpC3 is a newer and less-tested approach.
Where this research is happening
Milwaukee, United States
- Medical College of Wisconsin — Milwaukee, United States (Active)
Researchers
- Principal investigator: Lou, Xuelin — Medical College of Wisconsin
- Study coordinator: Lou, Xuelin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.